• You are here:  
  • Home
  • Press Release

Sabinsa Expands UK and EU Footprint with New Staff

Details
Press Release
1980
Sabinsa Expands UK and EU Footprint with New Staff

Sabinsa has opened two new satellite offices in the UK and in Spain to support customers in Europe. The Spanish office will service Spain, Portugal, the Iberian Peninsula, Southern France, and Northwestern Africa. The UK office will support customers in the UK and Ireland in navigating changes and challenges brought about by Brexit.

Sabinsa Reaches Intellectual Property Milestone with over 300 Patents Granted

Details
Press Release
1853
Sabinsa Cosmeceutical Ingredients COSMOS Approved

Sabinsa’s intellectual property portfolio now includes 308 separate patents granted across the world. The most recent patents granted include several from Australia, Canada, Europe, and the USA. Sabinsa’s patent portfolio includes composition, use and process patents. Many are for various aspects of category leader ingredients such as LactoSpore®, DigeZyme® and Curcumin C3 Complex®; others are for relatively new, up and coming ingredients such as Nigellin® and Sabroxy®.

Sabinsa Cosmeceutical Ingredients COSMOS Approved: Cococin™, Saberry®, and Nigellin® Amber

Details
Press Release
1933
Sabinsa Cosmeceutical Ingredients COSMOS Approved

Sabinsa has successfully completed the audit for several of its natural cosmetic ingredients as conforming to COSMOS standards, verified by Ecocert Greenlife: Cococin™ (Cocos nucifera liquid Endosperm), Saberry® (Emblica officinalis fruit extract) and Nigellin® Amber (Black seed extract).

Research Published on Sabinsa's Curcumin C3 Complex® / BioPerine® Combination as Adjuvant Therapy in COVID-19 Patients

Details
Press Release
1516
Research Published on Sabinsa's Curcumin C3 Complex<sup>®</sup>BioPerine<sup>®</sup> Combination as Adjuvant Therapy in COVID-19 Patients

Sabinsa's flagship combination product, Curcumin C3 Complex® with BioPerine® (525mg/2.5 mg twice a day, 14 days), was used as adjuvant therapy for COVID-19 in a double-blind, randomized controlled clinical trial conducted on COVID-19 patients in India, where the wide-spread virus infection has strained the healthcare system.

Court Orders Prakruti to Pay over $1 Million in Fees and Costs to Sabinsa as a Sanction For Discovery Abuses in Litigation

Details
Press Release
1621
Sabinsa as a Sanction For Discovery Abuses in Litigation

Sami-Sabinsa Group Limited, the world leader in Curcumin for the dietary supplements industry, has been awarded more than $1 Million in attorney’s fees and costs against Prakruti Products. The award, issued by a federal judge in New Jersey on May 24, came in the wake of Sabinsa’s successful prosecution of Prakruti’s egregious discovery misconduct. The Magistrate Judge had previously imposed non-monetary sanctions on Prakruti, and that ruling was affirmed by the District Judge on appeal. The award is Sabinsa’s latest win in a years-long discovery battle with Prakruti that began in June 2017, after the Court reopened a settled case involving Prakruti’s infringement of Sami-Sabinsa’s patented Curcumin C3 Complex®.

Sabinsa Founder Dr. Muhammed Majeed Named Father of Indian Nutraceuticals Industry by ASSOCHAM

Details
Press Release
1390
Sabinsa Founder Dr. Muhammed Majeed Named Father of Indian Nutraceuticals Industry by ASSOCHAM

Dr. Muhammed Majeed, founder of the Sami-Sabinsa Group, was named the Father of Indian Nutraceuticals Industry with an honorary award presented on the occasion of ASSOCHAM’s virtual conference entitled Efficacy of Herbal Nutraceuticals: Stimulating the New Lifestyle.

New Research Published on Sabinsa’s Curcumin C3 Reduct® Supports Efficacy as an Oral Care Ingredient

Details
Press Release
1529
Curcumin c3 Reduct

New research has recently been published that builds upon evidence from a previous trial investigating the potential of Sabinsa’s Curcumin C3 Reduct® ingredient in oral care applications.

Sabinsa Top Scientist Gives Presentation to U.S. FDA

Details
Press Release
1438
drkalyanam presentation

Dr. Kalyanam Nagabhushanam, President (R&D), Sabinsa Corporation presented, at the invitation of FDA, a seminar on December 10, 2020 to a group of US FDA scientists as part of the CDER Botanical Drug Seminar Series (BDSS).

Sabinsa Expands IP Portfolio with Five New U.S. Patents, Two CII Awards for IP Portfolio, and Dr. Majeed Honored by IASTAM

Details
Press Release
1403
Zandu-iastam-award

Sabinsa ends the year with more good news about achievements. The Confederation of Indian Industry (CII) recognized the Sami-Sabinsa Group with two awards for IP property, and Sami-Sabinsa Founder and Chairman, Dr. Muhammed Majeed, was honored by the Indian Association for the Study of Traditional Asian Medicine (IASTAM). Additionally, the company has been granted five new U.S. patents, including strengthening IP protection on its flag-ship probiotic, LactoSpore® with new applications, and additional patents for novel compositions.

Sabinsa’s Macumax® Formula Demonstrates Vision Health Benefits in Published Study

Details
Press Release
1468
Sabinsa cosmetics

Sabinsa’s proprietary formulation Macumax® was shown to have vision health benefits in a clinical trial on subjects diagnosed with age-related macular degeneration (AMD). The study An Open-Label Pilot Study on Macumax Supplementation for Dry-Type Age-Related Macular Degeneration authored by Muhammed Majeed, Shaheen Majeed and Kalyanam Nagabhushanam, was published in the Journal of Medicinal Food (ahead of print doi.org/10.1089/jmf.2020.0097).